According to a recent LinkedIn post from Andelyn Biosciences, the company plans to participate in the 29th ASGCT Annual Meeting in Boston from May 11–15, highlighting its experience in viral-vector manufacturing. The post points to a dedicated conference schedule and offers meetings with company experts at Booth #1025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Andelyn is prioritizing business development and visibility within the gene therapy ecosystem, using ASGCT as a venue to engage prospective partners and clients. For investors, this outreach may indicate an effort to expand its customer pipeline in viral-vector manufacturing, potentially supporting future revenue growth and reinforcing its positioning in the contract development and manufacturing segment of biotechnology.